SCHEMBL6705574

SCHEMBL6705574

CCCC(NCCc1ccccn1)c1ccc(N(Cc2ccc(O)cc2Cl)S(=O)(=O)c2c(C)cc(C)cc2C)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
GLA P06280 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TDP1 Q9NUW8 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
LMNA P02545 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
PKM P14618 1/20 0.34
SLC12A2 P55011 1/20 0.34
SLC12A5 Q9H2X9 1/20 0.34
ALDH1A1 P00352 2/20 0.33
TP53 P04637 1/20 0.32
TSHR P16473 1/20 0.32
KEAP1 Q14145 1/20 0.32
NFE2L2 Q16236 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6705584 0.80 GLA (0.38) MAPTGLAL3MBTL1TDP1CYP1A2
SCHEMBL6705581 0.78 GLA (0.39) MAPTGLAL3MBTL1TDP1CYP1A2
SCHEMBL5863647 0.72 RAPGEF4 (0.39) TSHRKEAP1NFE2L2GAANR3C1
SCHEMBL6705577 0.72 SLC40A1 (0.33) MAPTGLAL3MBTL1MEN1KMT2A
SCHEMBL5864026 0.72 KEAP1 (0.39) CYP2C9CYP2C19KEAP1NFE2L2NR3C1
SCHEMBL5863634 0.70 NR1H2 (0.38) TSHRKEAP1NFE2L2GAANR3C1
SCHEMBL5863809 0.66 CYP2D6 (0.48) MAPTGLAL3MBTL1TDP1CYP1A2
SCHEMBL5864051 0.65 ABL1 (0.40)
SCHEMBL5864216 0.65 SIGMAR1 (0.40) TDP1MEN1KMT2AALDH1A1KEAP1
SCHEMBL5864868 0.64 SIGMAR1 (0.38) CYP3A4CYP2D6ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110767-A1 Acyclic amide and sulfonamide ligands for the estrogen receptor PFIZER INC 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110767-A1 Acyclic amide and sulfonamide ligands for the estrogen receptor GHSR, GPER1, SSTR1 MAPT 4755/4885GLA 183/4885L3MBTL1 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.